Author

Min Shen

National Institutes of HealthORCID 0009-0001-9290-1855Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Min Shen3 papers · National Institutes of Health

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

Bereketeab HaileselassieiD· 1 shared Chandrayee GhoshiD· 1 shared Eden Demissie Alamaw· 1 shared Electron KebebewiD· 1 shared Jiangnan HuiD· 1 shared Maura J. O’NeilliD· 1 shared Myriem BoufraqechiD· 1 shared Tejinder Pal KhaketiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bereketeab HaileselassieORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintMar 19, 2026

Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

Tejinder Pal Khaket, Chandrayee Ghosh, Zhongyue Yang…·Electron Kebebew

This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.

DOI 10.64898/2026.03.15.711663

humanexperimental assay

𝕏 PostBluesky